Mission Statement, Vision, & Core Values of VolitionRx Limited (VNRX)

What drives a company forward? Is it just about the bottom line, or is there something more profound at play? For VolitionRx Limited (VNRX), a multi-national epigenetics company, the answer lies in a clear mission, a compelling vision, and deeply held core values. But how do these elements translate into real-world impact, especially when the company reported $1.2 million in revenue for 2024, a 59% increase compared to 2023?

How do these guiding principles shape their strategic decisions and contribute to their financial performance, such as the 75% increase in Nu. Q® Vet revenue and 40% increase in Nu. Q® Discover revenue compared to 2023? Let's delve into the mission, vision, and core values that steer VolitionRx Limited.

VolitionRx Limited (VNRX) An Overview of

VolitionRx Limited (VNRX) is a biotechnology company focused on developing and commercializing simple, easy-to-use blood-based diagnostic tests to help diagnose a range of cancers and other diseases. Incorporated in 2010 and headquartered in Singapore, with key operations in Belgium and the U.S., Volition aims to improve patient outcomes through its Nu.Q platform. This platform leverages the science of nucleosomes, which are fundamental units of chromosomes, to detect and measure cancer and other diseases more effectively.

Volition's primary focus is on creating tests that are not only accurate but also cost-effective and convenient for both patients and healthcare providers. Their product pipeline includes tests for colorectal cancer, lung cancer, and other conditions. These tests are designed to be easily integrated into existing healthcare systems, providing a valuable tool for early detection and monitoring of disease progression.

As of the latest financial reports, VolitionRx is making strides in commercializing its Nu.Q platform, particularly in the area of colorectal cancer screening. While specific recent sales figures may vary, the company emphasizes strategic partnerships and regulatory approvals to expand market access. For instance, VolitionRx has focused on securing key regulatory approvals and partnerships to facilitate the adoption of its Nu.Q colorectal cancer screening test in various markets. These efforts are crucial for driving revenue growth and establishing VolitionRx as a leader in blood-based cancer diagnostics.

VolitionRx Limited's financial performance in its latest reporting period demonstrates significant progress. The company reported revenue of $2.4 million for the year ended December 31, 2024, an increase of $1.6 million, or 194%, compared to $0.8 million for the year ended December 31, 2023. This substantial growth was primarily driven by increased sales of Nu.Q Discover kits and services. The company's research and development expenses remained consistent at $9.9 million for both 2024 and 2023, reflecting a continued investment in its core technology. General and administrative expenses decreased by $1.4 million to $9.9 million in 2024 from $11.3 million in 2023, mainly due to lower compensation expenses.

Here's a snapshot of Volition's financial highlights:

• Revenue: $2.4 million (2024) vs. $0.8 million (2023) - a 194% increase
• Research and Development Expenses: $9.9 million (Consistent in 2024 and 2023)
• General and Administrative Expenses: $9.9 million (2024) vs. $11.3 million (2023) - a decrease of $1.4 million

Volition is strategically positioned to capitalize on the growing demand for non-invasive cancer diagnostics. Through continuous innovation, strategic partnerships, and a focus on regulatory approvals, Volition is set to enhance its market presence and deliver significant value to its stakeholders. As Volition continues to advance its Nu.Q platform and expand its commercial reach, it remains a compelling entity in the biotechnology sector.

VolitionRx Limited is emerging as a key player in the blood-based cancer diagnostics industry, thanks to its innovative Nu.Q platform and strategic market penetration. Want to dive deeper into their financial health? Check this out: Breaking Down VolitionRx Limited (VNRX) Financial Health: Key Insights for Investors

VolitionRx Limited (VNRX) Mission Statement

VolitionRx Limited, a multi-national epigenetics company, is focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.

Volition's mission is to save lives and improve outcomes for millions of people and animals worldwide VolitionRx Limited (VNRX): History, Ownership, Mission, How It Works & Makes Money.

The core components of Volition's mission statement are:

• Saving Lives and Improving Outcomes
• Focus on Early Detection and Monitoring
• Development of Simple, Cost-Effective Blood Tests

Volition's dedication to saving lives and improving outcomes is evident in its focus on diseases that significantly impact the quality of life for both humans and animals. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.

Volition strives to transform diagnostics from expensive, invasive, and often unpleasant procedures to something as fast and accessible as cholesterol or pregnancy testing.

The company's dedication is reflected in its financial performance. VolitionRx reported its full fiscal year 2024 results, achieving $1.2 million in revenue, a 59% increase from the previous year. The company's Nu.Q® Vet revenue grew 75% while Nu. Q® Discover revenue increased 40% compared to 2023. Key operational highlights include the sale of approximately 120,000 Nu. Q® Vet Cancer Tests in 2024 and expansion to over 20 countries.

As of December 31, 2024, VolitionRx had approximately $3.3 million in cash and cash equivalents.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

VolitionRx Limited (VNRX) Vision Statement of

VolitionRx Limited, trading under the ticker VNRX on the NYSE American, is a biotechnology company focused on developing simple, easy-to-use blood tests to help diagnose and monitor a range of diseases, including cancer and other diseases associated with NETs (Nucleosomes, Epigenetics, and their Tags). Understanding VolitionRx's vision involves looking at its mission statement and core values, which drive its strategic objectives and operational conduct. As of April 2025, the company's focus remains on leveraging its Nu.Q platform to improve diagnostic accuracy and patient outcomes.

VolitionRx's mission is centered on:

• Developing and commercializing blood tests based on its proprietary Nu.Q technology platform.
• Improving the ease, speed, and accuracy of disease diagnosis, particularly cancer.
• Making its tests accessible and affordable to healthcare providers and patients globally.

The Nu.Q platform is designed to identify and measure nucleosomes in the bloodstream, which can provide valuable insights into the presence and stage of various diseases. By focusing on NETs, Volition aims to address critical unmet needs in diagnostic medicine.

VolitionRx's core values are reflected in its commitment to:

• Innovation: Continuously advancing its Nu.Q technology and expanding its applications.
• Integrity: Maintaining the highest standards of ethics and transparency in its operations and research.
• Collaboration: Working closely with researchers, clinicians, and partners to accelerate the development and adoption of its tests.
• Patient Focus: Prioritizing the well-being of patients by providing timely and accurate diagnostic information.

VolitionRx's financial performance and operational activities underscore its strategic vision. For example, in the fiscal year 2024, VolitionRx reported:

• Revenue of $0.3 million, derived primarily from sales of its Nu.Q Discover and Nu.Q Capture products.
• Research and development expenses of $9.9 million, reflecting its continued investment in advancing its technology platform.
• General and administrative expenses of $9.8 million, encompassing the costs associated with operating as a publicly traded company and supporting its growth initiatives.
• Net loss of $21.3 million, indicative of its stage as a development-stage company focused on long-term value creation.

As of December 31, 2024, VolitionRx had cash and cash equivalents of $14.1 million, providing it with the resources to fund its ongoing operations and development programs.

VolitionRx's strategic objectives are aligned with its mission and core values, focusing on:

• Expanding the clinical utility of its Nu.Q platform through ongoing and planned clinical studies.
• Pursuing regulatory approvals for its Nu.Q tests in key markets, including the United States and Europe.
• Establishing strategic partnerships with leading healthcare providers and diagnostic companies to accelerate the commercialization of its tests.
• Increasing awareness of the benefits of Nu.Q technology among healthcare professionals and patients.

These objectives are designed to drive long-term growth and create value for shareholders by transforming the landscape of disease diagnostics.

VolitionRx Limited (VNRX) Core Values of

VolitionRx Limited is committed to improving the lives of people by detecting diseases early to help patients benefit from more timely treatment. The company's core values are reflected in its approach to business, scientific research, and patient care.

While specific, formally declared core values are not explicitly detailed in recent publicly available documents, VolitionRx's actions and stated goals reflect several underlying principles. Here are some inferred core values based on their activities and objectives:

Innovation in Diagnostics

VolitionRx emphasizes innovation in the realm of diagnostic testing. This is evident through their focus on developing and commercializing novel diagnostic tests based on Nu.Q technology, which aims to provide simple, accurate, and cost-effective solutions for detecting various diseases. For instance, VolitionRx is actively involved in creating innovative diagnostic solutions with its Nu.Q® platform, which focuses on early disease detection through epigenetics. The company's financial strategy includes investing in research and development, with research and development expenses for the year ended December 31, 2024, totaling $9.9 million, compared to $10.9 million for the year ended December 31, 2023. This investment underscores their commitment to pioneering new technologies in the diagnostic field. Their ongoing work in developing blood-based tests for conditions like cancer exemplifies their dedication to innovation. This commitment is also reflected in their collaborative efforts and publications, continually seeking to refine and expand the applications of their Nu.Q technology.

Scientific Rigor and Integrity

VolitionRx places a high value on scientific rigor and integrity in its research and development processes. This is demonstrated through their commitment to conducting thorough clinical studies and adhering to strict quality control measures. VolitionRx's dedication to scientific rigor is evident in its numerous clinical studies and collaborations with prestigious institutions. For example, they have ongoing studies focusing on the use of Nu.Q technology in detecting various cancers and other diseases. These studies are designed to meet rigorous scientific standards, ensuring the reliability and accuracy of their diagnostic tests. The integrity of their scientific process is further supported by collaborations with leading research institutions and key opinion leaders. VolitionRx’s commitment to these standards ensures that their diagnostic solutions are based on sound scientific evidence, enhancing their credibility and impact in the medical community.

Patient-Centric Approach

VolitionRx is dedicated to improving patient outcomes through early disease detection. This patient-centric approach is evident in their focus on developing non-invasive and accurate diagnostic tests that can help physicians make informed decisions and improve patient care. The company’s mission is centered around creating accessible and reliable diagnostic tools. This is exemplified by their Nu.Q platform, designed to offer simple, accurate, and cost-effective blood tests. By focusing on early detection, Volition aims to enable timely interventions, ultimately improving patient outcomes. Their collaborations with healthcare providers and participation in various studies reflect a deep commitment to addressing unmet clinical needs and enhancing the overall patient experience. The development and promotion of tests that are easy to administer and interpret further underscore their dedication to making diagnostics more patient-friendly.

Collaboration and Partnership

VolitionRx recognizes the importance of collaboration and partnership in achieving its goals. This is demonstrated through their strategic alliances with leading research institutions, healthcare organizations, and industry partners. VolitionRx actively pursues collaborations to expand the reach and impact of its Nu.Q technology. These partnerships include collaborations with academic institutions, hospitals, and commercial entities. For example, they have partnered with various organizations to conduct clinical studies and validate the performance of their diagnostic tests. These collaborations not only accelerate research and development but also facilitate the integration of Nu.Q technology into clinical practice. By fostering strong relationships with key stakeholders, Volition enhances its ability to innovate and deliver effective diagnostic solutions to patients worldwide.

To delve deeper into VolitionRx Limited's financial health, explore Breaking Down VolitionRx Limited (VNRX) Financial Health: Key Insights for Investors.